Last $0.80 HKD
Change Today 0.00 / 0.00%
Volume 1.7M
775 On Other Exchanges
Hong Kong
As of 3:01 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

ck life sciences intl hldgs (775) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $0.92
52 Week Low
05/12/14 - $0.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CK LIFE SCIENCES INTL HLDGS (775)

Related News

No related news articles were found.

ck life sciences intl hldgs (775) Related Businessweek News

No Related Businessweek News Found

ck life sciences intl hldgs (775) Details

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, is engaged in the research and development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products; and contract manufactures complementary healthcare medicines and produces non-sterile prescription and over-the-counter medicines. The company is also involved in licensing registration activities and the importation of finished agricultural goods; holding land and building; financing, water treatment, and trustee activities; investment in financial instruments, as well as vineyards and wineries; trading biotechnology products and nutritional supplements; and the manufacture, wholesale, retail, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as chemicals and professional pest products; produces, refines, and distributes salt products; and provides services in the research and development of bio-technology and life sciences technology products. CK Life Sciences’ products include emulsifiable concentrates, suspension concentrates, aqueous solutions, coated granules, powders, and amination based reactions for crop protection; and pharmaceutical products, such as Tetrodotoxin and POL-103A that are in advanced stages of clinical development, as well as CKBP002 and CKBP004 that are in pre-clinical studies for the treatment of cancer. The company is headquartered in Tai Po, Hong Kong.

1,635 Employees
Last Reported Date: 08/5/14

ck life sciences intl hldgs (775) Top Compensated Officers

Chief Operating Officer, Vice President, Comp...
Total Annual Compensation: $9.1M
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $6.6M
Compensation as of Fiscal Year 2013.

ck life sciences intl hldgs (775) Key Developments

CK Life Sciences Int'l., (Holdings) Inc. Enter into New Supply Agreement with HIL Group

On 19 December 2014, CK Life Sciences Int'l., (Holdings) Inc. entered into the new HIL supply agreement for a term of three years commencing from 1 January 2015. As the applicable percentage ratios (other than the profits ratio) calculated in accordance with chapter 14A of the listing rules in respect of the estimated total amount of the New HIL Continuing Connected Transactions will, on an annual basis, be more than 0.1% but less than 5%, the New HIL Continuing Connected Transactions are exempt from the independent shareholders approval requirements under the listing rules, and are only subject to the reporting, announcement and annual review requirements under chapter 14A of the listing rules. Under the Existing HIL Supply Agreement, HIL engages the company and the company agrees to provide and/or procure to be provided the Products to the HIL Group for sale and distribution on a non-exclusive basis for a term from 1 January 2012 to 31 December 2014. In that connection, relevant members of the group may make the sales related payments to the relevant members of the HIL Group.

CK Life Sciences Int'l., (Holdings) Inc. Announces Unaudited Consolidated Financial Results for the Six Months Ended June 30, 2014

CK Life Sciences Int'l., (Holdings) Inc. announced unaudited consolidated financial results for the six months ended June 30, 2014. For the six months, the company reported Turnover HKD 2,416,792,000 against HKD 2,481,175,000 a year ago. Profit before taxation was HKD 169.965 million against HKD 178.677 million a year ago. Profit attributable to shareholders of the company was HKD 146.608 million or 1.53 cents per diluted share against HKD 139.928 million or 1.46 cents per diluted share a year ago. Net cash from operating activities was HKD 140.933 million against HKD 108.125 million a year ago.

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2014 Results on Jul 22, 2014

CK Life Sciences Int'l., (Holdings) Inc. announced that they will report first half, 2014 results on Jul 22, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
775:HK $0.80 HKD 0.00

775 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cheung Kong Holdings Ltd $145.40 HKD -0.40
Henderson Land Development Co Ltd $56.00 HKD +1.10
Real Nutriceutical Group Ltd $2.27 HKD -0.02
Tom Group Ltd $1.66 HKD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation 775 Industry Range
Price/Earnings 32.6x
Price/Sales 1.6x
Price/Book 1.5x
Price/Cash Flow 25.4x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CK LIFE SCIENCES INTL HLDGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at